Stentebjerg-Olesen Marie, Jeppesen Pia, Pagsberg Anne K, Fink-Jensen Anders, Kapoor Sandeep, Chekuri Raja, Carbon Maren, Al-Jadiri Aseel, Kishimoto Taishiro, Kane John M, Correll Christoph U
1 Mental Health Centre for Child and Adolescent Psychiatry , Glostrup, Denmark .
J Child Adolesc Psychopharmacol. 2013 Dec;23(10):665-75. doi: 10.1089/cap.2013.0007. Epub 2013 Nov 22.
The use of early response/nonresponse (ER/ENR) to antipsychotics as a predictor for ultimate response/nonresponse (UR/UNR) may help decrease inefficacious treatment continuation. However, data have been limited to adults, and ER/ENR has only been determined using time-consuming psychopathology rating scales. In the current study, we assessed if early improvement on the Clinical Global Impressions-Improvement (CGI-I) scale predicted UR/UNR in psychiatrically ill youth started on antipsychotic treatment.
Seventy-nine youth aged 6-19 years, with schizophrenia spectrum disorders, treated naturalistically with aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone and evaluated monthly, were divided into ER/ENR groups at week 4, using at least "minimally improved" on the CGI-I scale. Prediction using week 4 ER/ENR status for UR (CGI-I=at least "much improved"), effectiveness and adverse effect outcomes at 8-12 weeks were assessed.
At 4 weeks, 45.6% of subjects were ER and 54.4% were ENR without differences regarding baseline demographic, illness, and treatment variables, except for higher age (p=0.034) and maximum risperidone dose (p=0.0043) in ENR. ER/ENR status at 4 weeks predicted UR/UNR at week 12 significantly (p<0.0001): Sensitivity=68.9%, specificity=85.3%, positive predictive value=86.1%, negative predictive value=67.4%. At weeks 4, 8, and 12, ER patients improved significantly more on the CGI-I, CGI-Severity, and Children's Global Assessment of Functioning scales, and more ER patients reached UR compared with ENR patients (83.3% vs. 34.9%, all p<0.0001). ENR patients had more extrapyramidal side effects (EPS) at weeks 4, 8, and 12 (p=0.0019-0.0079). UR was independently associated with ER (odds ratio [OR]=18.09; 95% confidence interval [CI]=4.71-91.68, p<0.0001) and psychosis not otherwise specified (NOS) (OR=4.82 [CI: 1.31-21.41], p=0.017) (r(2)=0.273, p<0.0001).
Older age and EPS were associated with ENR; ENR and schizophrenia were associated with UNR in naturalistically treated youth with schizophrenia spectrum disorders. Early CGI-I-based treatment decisions require further consideration and study.
将抗精神病药物的早期反应/无反应(ER/ENR)用作最终反应/无反应(UR/UNR)的预测指标,可能有助于减少无效治疗的持续时间。然而,相关数据仅限于成年人,且ER/ENR仅通过耗时的精神病理学评定量表来确定。在本研究中,我们评估了在开始接受抗精神病药物治疗的精神病性障碍青少年中,临床总体印象改善量表(CGI-I)上的早期改善是否能预测UR/UNR。
79名年龄在6至19岁、患有精神分裂症谱系障碍的青少年,接受阿立哌唑、奥氮平、喹硫平、利培酮或齐拉西酮的自然主义治疗,每月进行评估。在第4周时,根据CGI-I量表上至少“稍有改善”,将他们分为ER/ENR组。评估使用第4周的ER/ENR状态预测UR(CGI-I=至少“明显改善”)、8至12周时的疗效和不良反应结果。
在第4周时,45.6%的受试者为ER,54.4%为ENR,除了ENR组年龄较大(p=0.034)和利培酮最大剂量较高(p=0.0043)外,在基线人口统计学、疾病和治疗变量方面无差异。第4周时的ER/ENR状态显著预测了第12周时的UR/UNR(p<0.0001):敏感性=68.9%,特异性=85.3%,阳性预测值=86.1%,阴性预测值=67.4%。在第4、8和12周时,ER组患者在CGI-I、CGI-严重程度和儿童总体功能评估量表上的改善明显更多,与ENR组患者相比,达到UR的ER组患者更多(83.3%对34.9%,所有p<0.0001)。ENR组患者在第4、8和12周时锥体外系副作用(EPS)更多(p=0.0019至0.0079)。UR与ER独立相关(优势比[OR]=18.09;95%置信区间[CI]=4.71至91.68,p<0.0001)以及未另行说明的精神病(NOS)(OR=4.82[CI:1.31至21.41],p=0.017)(r(2)=0.273,p<0.0001)。
年龄较大和EPS与ENR相关;在接受自然主义治疗的精神分裂症谱系障碍青少年中,ENR和精神分裂症与UNR相关。基于早期CGI-I的治疗决策需要进一步考虑和研究。